» Articles » PMID: 39347052

Factors Derived from Human Exfoliated Deciduous Teeth Stem Cells Reverse Neurological Deficits in a Zebrafish Model of Parkinson's Disease

Overview
Journal J Dent Sci
Specialty Dentistry
Date 2024 Sep 30
PMID 39347052
Authors
Affiliations
Soon will be listed here.
Abstract

Background/purpose: Mesenchymal stem cells exhibit therapeutic efficacy for brain injury. This study examined the effect of mesenchymal stem cells derived from human exfoliated deciduous teeth (SHED) on alleviating symptoms of Parkinson's disease (PD).

Materials And Methods: SHED were isolated to examine the biosafety and bioavailability of stem cells derived from human exfoliated deciduous teeth-derived conditioned medium (SHED-CM) for the alleviation of PD symptoms in a 6-hydroxydopamine (6-OHDA)-induced PD zebrafish model.

Results: SHED-CM administration did not induce neurological, skin or muscle toxicity in control zebrafish at any dose, and estrogen equivalent testing showed no chronic toxicants. Induction of PD with 6-OHDA suppressed zebra SHED-CM was administered to zebrafish treated with 6-OHDA to induce PD symptoms. Similar to nomifensine, a drug with proven anti-PD potential, SHED-CM repaired the motor deficiencies in the zebrafish PD model.

Conclusion: Our results indicate the biosafety of SHED-CM and its therapeutic potential in treating PD in a zebrafish model.

References
1.
Shimojima C, Takeuchi H, Jin S, Parajuli B, Hattori H, Suzumura A . Conditioned Medium from the Stem Cells of Human Exfoliated Deciduous Teeth Ameliorates Experimental Autoimmune Encephalomyelitis. J Immunol. 2016; 196(10):4164-71. DOI: 10.4049/jimmunol.1501457. View

2.
Vaz R, Outeiro T, Ferreira J . Zebrafish as an Animal Model for Drug Discovery in Parkinson's Disease and Other Movement Disorders: A Systematic Review. Front Neurol. 2018; 9:347. PMC: 5992294. DOI: 10.3389/fneur.2018.00347. View

3.
Vaughan R, Foster J . Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci. 2013; 34(9):489-96. PMC: 3831354. DOI: 10.1016/j.tips.2013.07.005. View

4.
Langston J . Parkinson's disease: current and future challenges. Neurotoxicology. 2002; 23(4-5):443-50. DOI: 10.1016/s0161-813x(02)00098-0. View

5.
Sanchez-Guajardo V, Barnum C, Tansey M, Romero-Ramos M . Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro. 2013; 5(2):113-39. PMC: 3639751. DOI: 10.1042/AN20120066. View